Fianlimab (lag-3 inhibitor) combined with libtayo® (cemiplimab) shows clinically meaningful and durable tumor responses across key advanced melanoma patient populations

Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-pd-1 alone in similar settings – per trial results to be presented in an oral session at asco
REGN Ratings Summary
REGN Quant Ranking